- Home
- PRT vs VNRX Comparison
PRT vs VNRX Comparison
Compare PRT & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- VNRX
- Stock Information
- Founded
- PRT 2017
- VNRX N/A
- Country
- PRT United States
- VNRX United States
- Employees
- PRT N/A
- VNRX N/A
- Industry
- PRT Oil & Gas Production
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PRT Energy
- VNRX Health Care
- Exchange
- PRT Nasdaq
- VNRX Nasdaq
- Market Cap
- PRT 48.2M
- VNRX 52.4M
- IPO Year
- PRT N/A
- VNRX N/A
- Fundamental
- Price
- PRT $3.98
- VNRX $0.69
- Analyst Decision
- PRT
- VNRX Strong Buy
- Analyst Count
- PRT 0
- VNRX 5
- Target Price
- PRT N/A
- VNRX $3.88
- AVG Volume (30 Days)
- PRT 28.4K
- VNRX 173.0K
- Earning Date
- PRT 08-13-2025
- VNRX 08-14-2025
- Dividend Yield
- PRT 10.94%
- VNRX N/A
- EPS Growth
- PRT 1.16
- VNRX N/A
- EPS
- PRT 0.44
- VNRX N/A
- Revenue
- PRT $6,314,770.00
- VNRX $1,319,252.00
- Revenue This Year
- PRT N/A
- VNRX $372.23
- Revenue Next Year
- PRT N/A
- VNRX $201.80
- P/E Ratio
- PRT $9.04
- VNRX N/A
- Revenue Growth
- PRT 1.82
- VNRX 35.10
- 52 Week Low
- PRT $3.26
- VNRX $0.40
- 52 Week High
- PRT $4.63
- VNRX $0.94
- Technical
- Relative Strength Index (RSI)
- PRT 45.31
- VNRX 54.01
- Support Level
- PRT $3.95
- VNRX $0.60
- Resistance Level
- PRT $4.05
- VNRX $0.80
- Average True Range (ATR)
- PRT 0.07
- VNRX 0.05
- MACD
- PRT -0.01
- VNRX -0.00
- Stochastic Oscillator
- PRT 27.27
- VNRX 61.23
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.